In a market flooded with software companies and consumer brands, Indo-MIM Limited is a rare breed- a deep-tech, capital-intensive, globally dominant Indian manufacturer that most retail investors have never heard of. Yet, this Bengaluru-based company is the single largest Metal Injection Molding (MIM) manufacturer in the world, commanding a 6.8% global market share; ahead of Chinese, German, and American peers.
It makes precision components that go inside fighter jets, surgical instruments, electric vehicles, and firearms- all manufactured in India, shipped to 52+ countries. This is not a story about a domestic play. This is a story about India punching above its weight in global precision manufacturing.
The IPO opens for subscription on July 23 and closes on July 27. The price band is set at ₹461–₹485 per share, with a lot size of 30 shares. The total issue size is ₹3,812 crore.
Founded in 1996 by Krishna Chivukula, an IIT Madras and Harvard MBA alumnus, Indo-MIM started with a single bet: that Metal Injection Molding, a niche but powerful manufacturing technology, would become indispensable to the world's most demanding industries. Three decades later, that bet has paid off spectacularly.
Metal Injection Molding (MIM) is a manufacturing process that combines the design flexibility of plastic injection molding with the material properties of metal. It is used to produce small, complex, high-precision components at scale; parts that are too intricate for traditional machining and too strong for plastic. Think: the tiny locking mechanism inside a surgical stapler, the fuel injector nozzle in a car engine, or the trigger assembly in a defense weapon.
What makes Indo-MIM special is that it doesn't just do MIM. Over the years, it has evolved into a multi-technology precision engineering platform, offering metal injection molding, investment casting, precision machining (micron-level tolerances), ceramic injection molding, metal 3D printing (binder jetting), plastic injection molding and rapid & conformal tooling.
This breadth means a customer, say, a global aerospace original equipment manufacturer- can come to Indo-MIM for multiple components across multiple technologies, making the company a one-stop precision manufacturing partner rather than a commodity supplier.
In FY26, the company manufactured over 9,000 product types and developed 608 new tools; roughly 45 to 50 new tools every single month, which is among the fastest new product introduction rates in the global MIM industry.
The global MIM market is expected to grow from USD 4 billion (CY2025) to USD 6.2 billion by CY2030 at a CAGR of 9.2%, driven by EV adoption, defense modernization, and medical device demand. India is among the fastest-growing MIM markets globally at a 10.3% CAGR.
Indo-MIM leads globally at 6.8% share, ahead of Chinese player GIAN (6.1%), Germany's GKN Powder Metallurgy (3.6%), and others. That said, Chinese manufacturers collectively control ~53% of the global market, making competitive pricing pressure a structural reality.
India is among the fastest-growing MIM markets globally, and Indo-MIM is perfectly positioned to capture both domestic and export demand from this growth.
This is where Indo-MIM separates itself from many IPO stories. The numbers are real, consistent, and improving.
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 2,870 | 3,329 | 4,192 |
| Revenue Growth | 6.6% | 16.0% | 25.9% |
| EBITDA (₹ Cr) | 743 | 932 | 1,070 |
| EBITDA Margin | 25.9% | 28.0% | 25.5% |
| PAT (₹ Cr) | 283 | 423 | 533 |
| PAT Margin | 9.9% | 12.7% | 12.7% |
| ROE | 14.0% | 19.9% | 21.3% |
| ROCE | 19.59% | 23.51% | 26.6% |
Three things stand out:
Revenue is accelerating- growth went from 6.6% to 16% to 25.9% in three consecutive years Margins are stable and healthy- EBITDA margins holding at 25–28% is noteworthy Return ratios are improving- ROE has gone from 14% to 21.3% in just two years, indicating increasingly efficient capital deployment
At the upper end of the price band (₹485), the company is being valued at approximately 43–45x FY26 earnings, a premium valuation, but one that reflects its global leadership and growth trajectory.
By End-Use Segment (FY26): Automotive leads at 24.6%, followed by Defense (18.7%), Medical (18.1%), Aerospace (12%), and Consumer (10.8%). The diversification across four high-growth, high-margin industries is a key strength. A slowdown in one sector is cushioned by others.
By Geography (FY26): North America dominates 43.7% of the revenue, followed by India at 22.8%, Europe at 20%, and the rest of the world at 13.5%.
The most interesting data point here: India's revenue share jumped from just 10% in FY25 to 22.8% in FY26 a near-doubling in one year. This is likely driven by India's defense indigenization push (Make in India) and the growing domestic automotive and medical device sectors. This domestic pivot is a significant long-term positive.
The company is a founder-led, family-controlled business- which cuts both ways.
Krishna Chivukula (CMD, 79) is the architect of Indo-MIM's global success. An IIT Madras graduate with an MBA from Harvard, he has spent over 30 years building this company from scratch into a global leader. His son, Krishna Chivukula Jr. (CEO, 54), runs day-to-day operations and has been with the company for over 21 years.
The promoter group- led by Green Meadows Investments Ltd, holds a commanding 92.94% pre-IPO stake, which will dilute post-listing but still leave promoters in firm control.
The board has four independent directors, three of whom are women; a positive governance signal.
No research article is complete without the risks. Here are the ones that demand attention:
1. The CMD's Disqualification History
This is the most significant governance red flag. Krishna Chivukula was disqualified as a director from November 2016 to October 2021 under Section 164(2)(a) of the Companies Act- a five-year period during which he was technically barred from holding directorship. The trigger was his association with Shiva Chem Technologies (India) Pvt. Ltd., a company struck off by the RoC Hyderabad for non-filing of financial statements. His DIN was eventually reactivated via court orders.
While this has been resolved, the fact that the CMD of a company seeking a ₹3,800 crore public listing was disqualified for five years is something investors must weigh carefully.
2. Contingent Liabilities- A 3.5x Jump in Two Years
This is perhaps the most financially material risk.
GST, Excise, and VAT demands more than doubled, climbing from ₹63.4 crore to ₹153.2 crore between FY24 and FY26, a jump of about 142%. Income tax demands saw an even steeper rise, surging over 32x from just ₹2.3 crore to ₹74.2 crore. As a result, total demands nearly quadrupled over the two-year period, growing from ₹65.7 crore to ₹227.4 crore, an increase of roughly 246%.
Management maintains these will not materialize, but the trajectory is alarming and warrants close monitoring post-listing.
3. Audit Trail Gaps
The auditors flagged that the accounting software does not record audit trail at the database level, and the feature was not enabled for certain masters including the chart of accounts and inventory master. The inventory software also lacks audit trail recording.
For a company going public, this is a basic governance expectation that hasn't been fully met. The auditors issued an unmodified opinion despite this- meaning the financials are considered reliable, but the gap itself is a concern.
4. Related Party Transactions- Large But Declining
The company transacted ₹255.1 crore with related parties in FY26- about 6.1% of revenue. While this is declining as a percentage, the absolute quantum is significant. These include remuneration to promoters and KMPs, rental payments, and dividends. All are claimed to be at arm's length.
5. IPO Proceeds: Debt Repayment, Not Growth
80% of the fresh issue (₹400 crore out of ₹500 crore) goes toward repaying existing debt. While this improves the balance sheet, it means the IPO is not funding a new factory, new technology, or market expansion. Investors are essentially helping the promoters clean up the balance sheet.
6. China Risk
Chinese manufacturers control ~53% of the global MIM market. Indo-MIM competes head-on with Chinese players who benefit from lower costs, government subsidies, and a massive domestic market. Any further cost compression from China could pressure Indo-MIM's margins and market share.
7. North America Concentration
With 43.7% of revenue from North America, any US macro slowdown, tariff escalation, or customer-specific issues could have an outsized impact on Indo-MIM's topline.
| Strengths | Concerns |
|---|---|
| #1 globally in MIM for 6 years | CMD's 5-year directorship disqualification |
| Revenue accelerating (25.9% YoY in FY26) | Contingent liabilities up 3.5x in 2 years |
| Healthy EBITDA margins (25–28%) | Audit trail deficiencies flagged |
| ROE improving: 14% → 21.3% | 80% IPO proceeds for debt repayment |
| 9,000+ products, 52+ countries | Heavy North America concentration (43.7%) |
| India revenue share doubled to 22.8% | Chinese competition (53% global market share) |
| Diversified across Auto, Defense, Medical, Aerospace | Family-controlled, promoter at 92.9% pre-IPO |
| Strong certifications (IATF, ISO 13485, AS 9100) | Premium valuation (~43–45x FY26 earnings) |
Indo-MIM is a genuinely rare IPO, a globally dominant Indian manufacturer in a niche but fast-growing technology space. The financials are strong, the business model is defensible, and the end-market tailwinds (defense, medical, aerospace, EV) are real and long-term.
But the red flags are not trivial. The CMD's disqualification history, the sharp rise in contingent liabilities, and the audit trail gaps are governance concerns that investors must factor in. The premium valuation leaves little room for error, and the debt-repayment-heavy use of proceeds means the IPO isn't funding the next phase of growth- it's cleaning up the past.
For investors who believe in India's precision manufacturing story and are comfortable with the governance nuances, Indo-MIM offers a compelling long-term narrative. For those who prioritize clean governance and growth-oriented capital deployment, the concerns above deserve serious weight.
Disclaimer: This AI-generated analysis, based on RHP/DRHP information, is for informational purposes only. Investors should conduct due diligence and consult financial advisors before making investment decisions. Past performance does not guarantee future results, and all investments carry inherent risks including potential loss of principal.
